Related Experiment Video

Updated: May 14, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Oncolytic vaccinia virus therapy of salivary gland carcinoma

Natalya Chernichenko1, Gary Linkov, Pingdong Li

  • 1Departments of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.

JAMA Otolaryngology-- Head & Neck Surgery
|February 23, 2013
PubMed
Abstract

Insights

An attenuated vaccinia virus (GLV-1h68) effectively infected and lysed human salivary gland carcinoma cells in preclinical studies. This oncolytic virus demonstrated significant tumor regression with no observed toxicity, supporting clinical trials.

Area of Science:

  • Oncolytic virotherapy
  • Cancer research
  • Virology

Background:

  • Salivary gland carcinomas are rare and aggressive cancers.
  • Current treatment options for salivary gland carcinomas have limitations.
  • Oncolytic viruses offer a novel therapeutic strategy.

Purpose of the Study:

  • To evaluate the efficacy of an attenuated vaccinia virus, GLV-1h68, against human salivary gland carcinoma.
  • To assess the oncolytic potential of GLV-1h68 in vitro and in vivo.

Main Methods:

  • Five human salivary gland carcinoma cell lines were used for in vitro studies.
  • GLV-1h68 infection, transgene expression, and cytotoxic effects were measured.
  • Orthotopic and flank tumor models were established for in vivo assessment.

Main Results:

  • All tested cell lines were susceptible to GLV-1h68 infection and lysis.
  • Three cell lines showed high sensitivity to low doses of the virus.
  • Intratumoral injection of GLV-1h68 led to significant tumor regression in both flank and parotid models without toxicity.

Conclusions:

  • Attenuated vaccinia virus (GLV-1h68) exhibits significant oncolytic activity against salivary gland carcinomas.
  • The findings support the potential of GLV-1h68 as a therapeutic agent for these cancers.
  • Further clinical investigation is warranted based on these promising preclinical results.

More Related Videos

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

Retroductal Submandibular Gland Instillation and Localized Fractionated Irradiation in a Rat Model of Salivary Hypofunction07:44

Retroductal Submandibular Gland Instillation and Localized Fractionated Irradiation in a Rat Model of Salivary Hypofunction

Published on: April 24, 2016

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...